Abstract
Drug addiction is a chronic, relapsing disorder that is characterized by a compulsion to take drug regardless of the adverse consequences that may ensue. Although the involvement of mesoaccumbal dopamine neurons in the initiation of drug abuse is well-established, neuroadaptations within the limbic cortical- striatopallidal circuit that occur as a consequence of repeated drug use are thought to lead to the behavioral dysregulation that characterizes addiction. Opioid receptors and their endogenous ligands are enriched in brain regions comprising this system and are, thus, strategically located to modulate neurotransmission therein. This article will review data suggesting an important role of mu-opioid receptor (MOPr) and delta opioid receptor (DOPr) systems in mediating the rewarding effects of several classes of abused drugs and that aberrant activity of these opioid systems may not only contribute to the behavioral dysregulation that characterizes addiction but to individual differences in addiction vulnerability.
Keywords: Opioid receptors, drug self-administration, enkephalin, endorphin, cocaine, ethanol, morphine
CNS & Neurological Disorders - Drug Targets
Title: Targeting Endogenous Mu- and Delta-Opioid Receptor Systems for the Treatment of Drug Addiction
Volume: 7 Issue: 5
Author(s): T. S. Shippenberg, A. LeFevour and V. I. Chefer
Affiliation:
Keywords: Opioid receptors, drug self-administration, enkephalin, endorphin, cocaine, ethanol, morphine
Abstract: Drug addiction is a chronic, relapsing disorder that is characterized by a compulsion to take drug regardless of the adverse consequences that may ensue. Although the involvement of mesoaccumbal dopamine neurons in the initiation of drug abuse is well-established, neuroadaptations within the limbic cortical- striatopallidal circuit that occur as a consequence of repeated drug use are thought to lead to the behavioral dysregulation that characterizes addiction. Opioid receptors and their endogenous ligands are enriched in brain regions comprising this system and are, thus, strategically located to modulate neurotransmission therein. This article will review data suggesting an important role of mu-opioid receptor (MOPr) and delta opioid receptor (DOPr) systems in mediating the rewarding effects of several classes of abused drugs and that aberrant activity of these opioid systems may not only contribute to the behavioral dysregulation that characterizes addiction but to individual differences in addiction vulnerability.
Export Options
About this article
Cite this article as:
Shippenberg S. T., LeFevour A. and Chefer I. V., Targeting Endogenous Mu- and Delta-Opioid Receptor Systems for the Treatment of Drug Addiction, CNS & Neurological Disorders - Drug Targets 2008; 7 (5) . https://dx.doi.org/10.2174/187152708786927813
DOI https://dx.doi.org/10.2174/187152708786927813 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Current Medicinal Chemistry A Brief Review of circRNA Biogenesis, Detection, and Function
Current Genomics Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease
Current Alzheimer Research Targeting the Progression of Parkinsons Disease
Current Neuropharmacology Cannabinoids and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Targeted Therapy of Breast Cancer
Current Pharmaceutical Design Amorphous and Crystalline Particulates: Challenges and Perspectives in Drug Delivery
Current Pharmaceutical Design Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions
Current Protein & Peptide Science Nanoparticles-Based Treatment for Bone Metastasis
Current Drug Targets The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders
Current Pharmaceutical Design Editorial (Thematic Issue:Neuroscience of Exercise: Focus on Cognitive and Brain Functioning)
CNS & Neurological Disorders - Drug Targets Simultaneous Determination of Total Cortisol and Cortisone in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry: Method Development, Validation and Preliminary Clinical Application
Current Pharmaceutical Analysis Neuroimaging of Serotonin System in Anxiety Disorders
Current Pharmaceutical Design Daidzein and its Effects on Brain
Current Medicinal Chemistry Health Anxiety (Hypochondriasis): an Emotional Disorder in An Alternative Taxonomy
Current Psychiatry Reviews Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery The Nervous System as a Critical Regulator of Immune Responses Underlying Allergy
Current Pharmaceutical Design Sleep and Antidepressant Treatment
Current Pharmaceutical Design Chemokines and Their Receptors: Potential Therapeutic Targets for Bone Cancer Pain
Current Pharmaceutical Design Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease
Current Pharmaceutical Design